See More

See more with Aspaveli

See more with Aspaveli

Aspaveli is indicated in the treatment of adult patients with PNH who are anaemic after treatment with a C5i for at least 3 months*1

*Based on the approved indication for Aspaveli by the European Medicines Agency.

See the possibilities with Aspaveli:

 Bring control upstream
Hb Levels
Clinically meaningful improvements
give patients the assurance
self-infused to suit patients' lifestyles

†The most commonly reported adverse reactions in patients treated with Aspaveli were injection-site reactions: Injection-site erythema, injection-site pruritus, injection-site swelling, injection-site pain. Please refer to the Aspaveli Summary of Product Characteristics for further information.
C5i=complement 5 inhibitor; EVH=extravascular haemolysis; Hb=haemoglobin; IVH=intravascular haemolysis; PNH=paroxysmal nocturnal haemoglobinuria. 

References: 1. Aspaveli (pegcetacoplan) Summary of Product Characteristics. 2021. 2. Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384:1028–1037.